FANCONI SYNDROME

✓ Medically ReviewedDISEASEID: MDBT0258🚨 TRIAGE: URGENTICD-10: E72.0

📖

Definition

CLINICAL DEFINITION

Fanconi syndrome is a generalized disorder of the proximal renal tubule characterised by impaired reabsorption of amino acids, glucose, uric acid, phosphates, and bicarbonate, leading to their excessive excretion in the urine. It results in a combination of normoglycaemic glycosuria, aminoaciduria, phosphaturia, and Type 2 (proximal) renal tubular acidosis.

IN PLAIN ENGLISH

Fanconi syndrome is a condition where the kidney's filtering tubes fail to reabsorb important nutrients and minerals, causing them to be lost in the urine instead of returning to the blood. This can lead to poor growth, weak bones, and dehydration.

COMMON MISCONCEPTION / WHAT IT DOES NOT MEAN

Fanconi syndrome is NOT Fanconi anaemia. Fanconi anaemia is a completely unrelated inherited DNA repair disorder that causes bone marrow failure and physical abnormalities, whereas Fanconi syndrome is a renal tubular transport defect.

🔤

Word Breakdown

Fanconi

=Eponym for Guido Fanconi (1892–1979)

Literal Meaning: Named after the Swiss paediatrician Guido Fanconi, who extensively described the condition in the 1930s.

🔄

Synonyms & Variants

Renal Fanconi Syndrome›De Toni-Debré-Fanconi Syndrome›Fanconi Renotubular Syndrome›

🎯

Category-Specific Context

As a Disease, Fanconi syndrome represents a functional and structural failure of the proximal convoluted tubule (PCT). It can be inherited (primary) or acquired (secondary), acting as a final common pathway for various metabolic, genetic, or toxic insults that disrupt PCT transport mechanisms.

🏥

Clinical Context & Usage

CLINICAL SETTINGS

Paediatric NephrologyAdult NephrologyMetabolic Disease ClinicsHIV / Infectious Disease ClinicsHaematology / Oncology Wards

USAGE & DOCUMENTATION NOTES

Clinicians typically refer to 'Fanconi syndrome' or 'renal Fanconi syndrome' to distinguish it from Fanconi anaemia. Documentation often highlights the specific transport defects present, such as 'Type 2 RTA with phosphaturia and aminoaciduria'. In acquired cases, the underlying cause is usually appended, e.g., 'tenofovir-induced Fanconi syndrome' or 'myeloma-associated Fanconi syndrome'.

🔬

Primary Causes & Pathophysiology

PATHOPHYSIOLOGY

The proximal convoluted tubule (PCT) is responsible for reabsorbing the majority of filtered glucose, amino acids, uric acid, phosphate, and bicarbonate. In Fanconi syndrome, cellular injury or genetic defects in PCT transport proteins (such as the Na+/K+-ATPase pump or specific solute carriers) impair these reabsorptive processes. This leads to massive urinary losses of these essential solutes. The loss of bicarbonate causes a normal anion gap metabolic acidosis (Type 2 proximal renal tubular acidosis). Phosphate wasting leads to hypophosphataemia, which impairs bone mineralisation and causes rickets in children or osteomalacia in adults. Intracellular accumulation of toxic metabolites (e.g., cystine crystals in cystinosis or light chains in multiple myeloma) or direct mitochondrial toxicity from drugs (e.g., tenofovir) are common mechanisms of PCT injury.

PRIMARY CAUSES

Cystinosis

Autosomal recessive defect in the CTNS gene leads to lysosomal accumulation of cystine crystals in proximal tubule cells, causing progressive cellular injury and transport failure.

Multiple Myeloma

Monoclonal free light chains are filtered and endocytosed by proximal tubule cells, where they resist lysosomal degradation and accumulate, causing direct tubular toxicity.

Wilson Disease

Copper accumulation in the liver spills into the blood and deposits in the kidneys, causing oxidative damage and mitochondrial dysfunction in the proximal tubules.

Lowe Syndrome (Oculocerebrorenal Syndrome)

X-linked recessive mutation in the OCRL gene impairs inositol polyphosphate metabolism, disrupting proximal tubule cytoskeletal and transport functions.

Tyrosinaemia Type 1

Accumulation of toxic metabolites like succinylacetone causes severe oxidative stress and mitochondrial damage in proximal tubule cells.

💊

Drug-Induced Causes

💊 Tenofovir (antiretroviral) ↗

Mechanism: Accumulates in proximal tubule cells via organic anion transporters, causing mitochondrial DNA depletion and severe energy failure.

→ Discontinue tenofovir immediately. Provide aggressive electrolyte and bicarbonate replacement. Renal function usually recovers over weeks to months.

💊 Outdated Tetracyclines ↗

Mechanism: Degradation products (e.g., epianhydrotetracycline) are directly toxic to proximal tubule cells, causing reversible transport defects.

→ Stop the offending drug. Provide supportive fluid and electrolyte management. Tubular function typically recovers completely after withdrawal.

💊 Ifosfamide (chemotherapy) ↗

Mechanism: Metabolised to chloroacetaldehyde, which depletes cellular glutathione and causes severe mitochondrial toxicity in the PCT.

→ Discontinue ifosfamide. Administer IV fluids and correct electrolyte derangements. Co-administration of mesna may reduce urothelial toxicity but does not fully prevent tubular injury.

💊 Aminoglycosides ↗

Mechanism: Accumulate in proximal tubule lysosomes, causing phospholipidosis and disrupting cellular transport mechanisms.

→ Stop the antibiotic. Monitor renal function and electrolytes closely. Provide supportive replacement for urinary losses.

🌍

Epidemiology

Prevalence:Inherited forms are rare; nephropathic cystinosis occurs in approximately 1 to 2 per 100,000 to 200,000 live births globally. Acquired forms are more common in specific populations, such as patients with multiple myeloma or those receiving prolonged tenofovir therapy.

Age Group:Inherited forms typically present in infancy or early childhood. Acquired forms present in adulthood, depending on the onset of the underlying malignancy or drug exposure.

Sex Predilection:Equal

Geographic Distribution:Globally distributed, though certain genetic forms have founder effects (e.g., specific CTNS mutations in French Canadian populations).

Red Flags & Triage ★

TRIAGE LEVEL

🚨 URGENT

DO NOT MISS — LIFE-THREATENING PRESENTATIONS

Normoglycaemic glycosuria: raises suspicion for proximal tubular dysfunction rather than diabetes mellitus; requires evaluation for Fanconi syndrome and underlying causes like multiple myeloma in adults or cystinosis in children.
Unexplained hypophosphataemic rickets in a child: raises concern for renal phosphate wasting; requires evaluation for Fanconi syndrome to prevent severe bone deformities and growth failure.

URGENT EVALUATION TRIGGERS

Severe hypokalaemia (e.g., < 2.5 mmol/L) — risk of life-threatening arrhythmias and muscle paralysis.
Severe normal anion gap metabolic acidosis (e.g., serum bicarbonate < 12 mmol/L) — requires urgent intravenous bicarbonate replacement and electrolyte management.
Acute kidney injury superimposed on chronic tubular dysfunction — requires urgent fluid and electrolyte assessment.

Contraindications & Precautions

CONTRAINDICATIONS

Nephrotoxic medications — avoid concurrent use of other nephrotoxic agents (e.g.
NSAIDs
aminoglycosides
IV contrast) whenever possible.
Carbonic anhydrase inhibitors (e.g.
acetazolamide) — contraindicated as they worsen bicarbonate wasting and metabolic acidosis.

SPECIAL PRECAUTIONS

Monitor serum electrolytes (potassium
phosphate
bicarbonate) and renal function frequently when initiating known tubulotoxic drugs like tenofovir or ifosfamide.
Ensure adequate hydration to prevent volume depletion from osmotic diuresis caused by glycosuria and aminoaciduria.
Adjust doses of renally excreted medications based on the patient's declining glomerular filtration rate as tubulointerstitial disease progresses.

Complications

DOWNSTREAM CLINICAL COMPLICATIONS

Rickets and osteomalacia — chronic phosphate wasting impairs bone mineralisation
leading to skeletal deformities and fractures.
Type 2 (proximal) renal tubular acidosis — bicarbonate wasting causes chronic normal anion gap metabolic acidosis
which can exacerbate bone disease and impair growth.
Growth retardation — chronic acidosis
electrolyte imbalances
and bone disease severely impair linear growth in children.
Chronic kidney disease — progressive tubulointerstitial fibrosis eventually leads to end-stage renal disease (ESRD)
particularly in untreated cystinosis.

🔀

Confused With (LASA & DDx) ★

LEXICAL (LASA) — SIMILAR NAMES

Fanconi Anaemia

Shares the eponym but is an entirely distinct genetic disorder involving defective DNA repair, characterised by pancytopenia, short stature, and radial ray anomalies, not renal tubular dysfunction.

CLINICAL DIFFERENTIAL DIAGNOSES (DDx)

Diabetes Mellitus

Key Distinguishing Feature: Causes glycosuria but is accompanied by hyperglycaemia; Fanconi syndrome features normoglycaemic glycosuria.

Isolated Renal Glycosuria

Key Distinguishing Feature: Benign SGLT2 mutation causing isolated glucose loss in urine without aminoaciduria, phosphaturia, or metabolic acidosis.

Type 1 (Distal) Renal Tubular Acidosis

Key Distinguishing Feature: Features normal anion gap metabolic acidosis and hypokalaemia, but urine pH is inappropriately high (>5.5) and there is no glycosuria or aminoaciduria.

💎

Clinical Pearls

💎

Fanconi syndrome causes normoglycaemic glycosuria. If a patient has glucose in the urine but normal blood glucose, think proximal tubule defect, not diabetes mellitus.

💎

Always distinguish Fanconi syndrome (renal tubular defect) from Fanconi anaemia (inherited DNA repair defect causing bone marrow failure). They are entirely unrelated and require completely different management.

💎

In adults presenting with acquired Fanconi syndrome, always screen for monoclonal gammopathies (e.g., multiple myeloma, MGUS) as light chain toxicity is a leading cause.

💎

Outdated tetracycline antibiotics can degrade into nephrotoxic compounds (epianhydrotetracycline) that cause reversible Fanconi syndrome; always check medication expiration dates and storage conditions.

📝

Example Usage & SOAP

CLINICAL SENTENCE

"The patient presented with failure to thrive and polyuria; laboratory investigations revealed normoglycaemic glycosuria, aminoaciduria, and hypophosphataemia, consistent with Fanconi syndrome secondary to cystinosis."

IN A SOAP NOTE

S: 4-year-old boy presents with poor weight gain, excessive thirst, and polyuria over the past 6 months. O: Vitals: HR 110, BP 90/60. Growth parameters: weight and height < 3rd percentile. Mild frontal bossing and bowing of the legs noted. Labs: Serum Na 138 mmol/L, K 2.8 mmol/L, Cl 110 mmol/L, HCO3 16 mmol/L, Glucose 4.5 mmol/L, Phosphate 0.6 mmol/L. Urinalysis: 3+ glucose, 2+ protein, pH 6.0. Urine amino acids markedly elevated. A: Fanconi syndrome with Type 2 RTA and hypophosphataemic rickets, likely secondary to nephropathic cystinosis. P: Admit for IV fluid and electrolyte correction (K and bicarbonate). Start oral phosphate and calcitriol. Order leukocyte cystine levels and genetic testing for CTNS gene mutations. Ophthalmology consult for corneal crystals.

DIFFERENTIAL DIAGNOSIS CONTEXT

Differential for normoglycaemic glycosuria and hypophosphataemia: (1) Fanconi syndrome (generalized PCT defect causing aminoaciduria, phosphaturia, and Type 2 RTA); (2) Isolated renal glycosuria (benign SGLT2 mutation, no other electrolyte abnormalities); (3) X-linked hypophosphataemia (isolated phosphate wasting without glycosuria or aminoaciduria); (4) Osmotic diuresis (typically associated with hyperglycaemia).

📈

Prognosis

SHORT-TERM OUTCOME

Drug-induced or toxin-induced Fanconi syndrome is often fully reversible within weeks to months if the offending agent is removed promptly and electrolytes are corrected.

LONG-TERM PROGNOSIS

Inherited forms like cystinosis typically progress to end-stage renal disease in the first or second decade of life without early initiation of cystine-depleting therapy (cysteamine). With optimal therapy, renal survival is significantly prolonged, but extrarenal complications (e.g., myopathy, endocrinopathies) may develop in adulthood.

📚

References & Coding

ICD-10 DIAGNOSTIC CODE

E72.0

LITERATURE CITATIONS & GUIDELINES

[1]Cherqui S. The renal Fanconi syndrome in cystinosis: Pathogenic insights and therapeutic perspectives. Nat Rev Nephrol. 2017;13(2):115-131.

[2]Hall AM, Bass P, Unwin RJ. Drug-induced renal Fanconi syndrome. QJM. 2014;107(4):261-269.

[3]Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Drug-induced Fanconi's syndrome. Am J Kidney Dis. 2003;41(2):292-309.

MEDICAL DISCLAIMER — This content is intended for educational purposes and qualified healthcare professionals only. Always refer to current clinical diagnostic criteria, institutional protocols, and official guidelines. Medobo is not responsible for clinical decisions made based on this content.